{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T22:42:38Z","timestamp":1790030558608,"version":"4.0.1"},"reference-count":12,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2012,7,26]],"date-time":"2012-07-26T00:00:00Z","timestamp":1343260800000},"content-version":"vor","delay-in-days":9825,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[1985,9]]},"abstract":"<jats:p>Single dose pharmacokinetics of oxazepam, 30 mg, have been studied in six healthy male volunteers in the absence of diflunisal and during continuous treatment with diflunisal 500 mg twice daily. During diflunisal treatment, peak plasma concentration of oxazepam significantly decreased from 387 +\/\u2010 18 ng ml\u20101 (mean +\/\u2010 s.e. mean) to 241 +\/\u2010 10 ng ml\u20101 and total area under the plasma concentration\u2010time curve (AUC) significantly decreased from 5536 +\/\u2010 819 ng ml\u20101 h to 4643 +\/\u2010 562 ng ml\u20101 h. The AUC of oxazepam glucuronide significantly increased from 4771 +\/\u2010 227 ng ml\u20101 h to 8116 +\/\u2010 644 ng ml\u20101 h and its elimination half\u2010life increased from 10.0 +\/\u2010 0.6 h to 13.0 +\/\u2010 1.0 h. Renal clearance for oxazepam glucuronide was significantly reduced from 74 +\/\u2010 2 ml min\u20101 to 46 +\/\u2010 3 ml min\u20101. In vitro, diflunisal, at concentrations of 125 to 1000 micrograms ml\u20101, significantly displaced oxazepam from its plasma protein binding, the free fraction of oxazepam increasing by 28 to 56%. The free fraction of oxazepam glucuronide, ex vivo, increased by 49 +\/\u2010 5% (n = 3) during concomitant diflunisal treatment. These data suggest that the observed interaction between oxazepam and diflunisal results from a presystemic displacement of oxazepam from its plasma protein binding sites by diflunisal and from an inhibition of the tubular secretion of oxazepam glucuronide by the glucuronides of diflunisal.<\/jats:p>","DOI":"10.1111\/j.1365-2125.1985.tb05065.x","type":"journal-article","created":{"date-parts":[[2012,7,26]],"date-time":"2012-07-26T21:46:00Z","timestamp":1343339160000},"page":"225-234","source":"Crossref","is-referenced-by-count":14,"title":["The influence of diflunisal on the pharmacokinetics of oxazepam."],"prefix":"10.1111","volume":"20","author":[{"given":"AM","family":"van Hecken","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"TB","family":"Tjandramaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Verbesselt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PJ","family":"de Schepper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,7,26]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198106020-00001"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/0009-8981(83)90086-4"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01721923"},{"key":"e_1_2_1_5_1","first-page":"569","article-title":"Inhibition of mor\u2010phine glucuronidation by oxazepam in human fetal liver microsomes","volume":"9","author":"Pacifici G. M.","year":"1981","journal-title":"Drug Metab. Dispos."},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/0003-2697(77)90043-4"},{"key":"e_1_2_1_7_1","first-page":"7","article-title":"Symbols in pharmacokinetics","volume":"14","author":"Rowland M.","year":"1982","journal-title":"Br. J. clin. Pharmac."},{"key":"e_1_2_1_8_1","first-page":"36","article-title":"Inhibition of indomethacin glucuronide formation by diflunisal","volume":"5","author":"Tjandramaga T. B.","year":"1983","journal-title":"Pharmaceutisch Weekblad Scientific Edition"},{"key":"e_1_2_1_9_1","first-page":"453","article-title":"Physiological disposition and metabolism of 5\u2010(2\u2032,4\u2032\u2010difluoro\u2010phenyl) salicylic acid, a new salicylate","volume":"3","author":"Tocco D. J.","year":"1975","journal-title":"Drug Metab. Dispos."},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(80)90378-0"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1979.tb00932.x"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(00)81842-3"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1975184377"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.1985.tb05065.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.1985.tb05065.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T15:50:04Z","timestamp":1697817004000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.1985.tb05065.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1985,9]]},"references-count":12,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1985,9]]}},"alternative-id":["10.1111\/j.1365-2125.1985.tb05065.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.1985.tb05065.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[1985,9]]}}}